Dr Dawson is chief of Adolescent Medicine Services, Carl R Darnall Army Medical Center Pediatric Clinic, Fort Hood, Texas.

Nipocalimab is the first FDA-approved therapy specifically for wAIHA, indicated for patients 12 and older previously or currently treated with corticosteroids. In the Phase 2/3 ENERGY trial, roughly ...

The position paper prioritizes rapid blood-culture diagnostics paired with stewardship, sub-1-hour antibiotic delivery in septic shock, and prolonged β-lactam infusion as Tier 1, evidence-backed ...

Lisa Swanson, MD, returns to diagnostic pitfalls, describing a presentation she sees often: AD in the crease of an infant's neck, which is frequently misdiagnosed as a yeast infection. Lisa Swanson, ...

Lisa Swanson, MD, describes AD as fundamentally unpredictable — a roller coaster of flares and quiet stretches that can wear down patients and families alike. Lisa Swanson, MD, describes AD as ...

Early antiviral therapy was associated with an 81% lower risk of influenza-related hospitalization among pediatric outpatients. The association was similar across age groups, including an 81% lower ...

Ecopipam is a first-in-class D1 receptor antagonist under FDA priority review for pediatric Tourette syndrome, with a decision expected in early 2027. Phase 3 data showed a 53% reduction in relapse ...

Lisa Swanson, MD, describes AD as fundamentally unpredictable — a roller coaster of flares and quiet stretches that can wear down patients and families alike.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Here: a "how to" on Gomco circumcision, the method most commonly used in the US. Although circumcision is commonly thought to have originated with Abraham (the patriarch of the Israelites) some 4000 ...

The mother of a 5-week-old boy was concerned about a swelling under her infant’s right nipple. A 2-cm, movable subareolar mass was palpated on examination. The mother of a 5-week-old boy was concerned ...

Prior to approval on February 14, 2025, the only FDA approved vaccine for chikungunya protection was indicated for 18 years and up. On March 18, 2025, Bavarian Nordic A/S announced the US commercial ...